Persistent Asset Partners LTD Summit Therapeutics Inc. Transaction History
Persistent Asset Partners LTD
- $121 Billion
- Q4 2024
A detailed history of Persistent Asset Partners LTD transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Persistent Asset Partners LTD holds 60 shares of SMMT stock, worth $1,383. This represents 0.01% of its overall portfolio holdings.
Number of Shares
60Holding current value
$1,383% of portfolio
0.01%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
231Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$563 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$269 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$182 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$151 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$129 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...